Professor LAO Shaoxian's clinical thinking and experience extraction of the treatment in gastric precancerous lesions by using the academic thought of "combination of disease, pattern and symptom"
-
摘要: 胃黏膜异型增生属于胃癌前病变的典型病理改变。通过多年的潜心研究，劳绍贤教授认为胃癌前病变的主要病机以脾胃气阴两虚为本，气滞血瘀、热毒内蕴为标；在健脾养阴基础上，提出以“清热以防变，祛瘀以通络”核心治法，强调针对具体病理改变施以专药的重要性，并结合多年的研究及临证经验拟定“抗增生方”治疗胃黏膜异型增生疗效较好，同时列举典型病例加以佐证；充分体现了劳绍贤教授提出的以“证为本、病为枢、症为标”的现代中医临证思维，可为中医药治疗胃癌前病变提供新视角。Abstract: Gastric mucosal dysplasia is a typical pathological change of gastric precancerous lesions. Through years of painstaking research, Professor LAO Shaoxian believes that the main pathogenesis of gastric precancerous lesions is "dual deficiency of qi and yin of the spleenod and stomach, blood stasis due to qi stagnation, heat toxin is the excess"; the core treatment method is "clear heat from preventing changes, removing blood stasis to dredge collaterals". LAO Shaoxian emphasizes the importance of applying special medicines for specific pathological changes, and combines years of research and clinical experience to formula "Kangzengsheng Fang" in the treatment of dysplasia. At the same time, typical cases are cited to support the curative effect. It fully embodies the modern Traditional Chinese Medicine clinical thinking of "pattern-based, disease-centered, and symptom-based" proposed by Professor LAO Shaoxian, which can provide a certain new perspective for the treatment of gastric precancerous lesion s by Traditional Chinese Medicine.
-
-
[1] Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. JNCC, 2022, 2(1): 1-9.
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. Ca Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
[3] Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention[J]. Cancer Res, 1992, 52(24): 6735-6740.
[4] Piazuelo MB, Bravo LE, Mera RM, et al. The Colombian Chemoprevention Trial: 20-Year Follow-Up of a Cohort of Patients With Gastric Precancerous Lesions[J]. Gastroenterology, 2021, 160(4): 1106-1117. doi: 10.1053/j.gastro.2020.11.017
[5] Shao L, Li P, Ye J, et al. Risk of gastric cancer among patients with gastric intestinal metaplasia[J]. Int J Cancer, 2018, 143(7): 1671-1677. doi: 10.1002/ijc.31571
[6] 王萍, 李鹏, 陈萦晅, 等. 中国整合胃癌前病变临床管理指南[J]. 胃肠病学, 2021, 26(2): 91-111. https://www.cnki.com.cn/Article/CJFDTOTAL-WIEC202102005.htm
[7] 国家消化系疾病临床医学研究中心(上海), 国家消化道早癌防治中心联盟, 中华医学会消化病学分会幽门螺杆菌学组, 等. 中国胃黏膜癌前状态和癌前病变的处理策略专家共识(2020年)[J]. 中华消化杂志, 2020, 40(11): 731-741. doi: 10.3760/cma.j.cn311367-20200915-00554
[8] Dinis-Ribeiro M, Areia M, de Vries A, et al. Management of precancerous conditions and lesions in the stomach(MAPS): guideline from the European Society of Gastrointestinal Endoscopy(ESGE), European Helicobacter Study Group(EHSG), European Society of Pathology(ESP), and the Sociedade Portuguesa de Endoscopia Digestiva(SPED)[J]. Endoscopy, 2012, 44(1): 74-94. doi: 10.1055/s-0031-1291491
[9] Kato M. Diagnosis and therapies for gastric non-invasive neoplasia[J]. World J Gastroenterol, 2015, 21(44): 12513. doi: 10.3748/wjg.v21.i44.12513
[10] Kato M, Nishida T, Tsutsui S, et al. Endoscopic submucosal dissection as a treatment for gastric noninvasive neoplasia: a multicenter study by Osaka University ESD Study Group[J]. J Gastroenterol, 2011, 46(3): 325-331. doi: 10.1007/s00535-010-0350-1
[11] Kato M, Ono S, Mabe K, et al. After endoscopic treatment of early stage gastric cancer[J]. Nihon Rinsho, 2013, 71(8): 1429-1435.
[12] Choi J, Kim SG, Yoon H, et al. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma[J]. Clin Gastroenterol Hepatol, 2014, 12(5): 793-800. doi: 10.1016/j.cgh.2013.09.057
[13] Chen X, Dai Y, Zhang Y, et al. Efficacy of traditional Chinese Medicine for gastric precancerous lesion: A meta-analysis of randomized controlled trials[J]. Complement Ther Clin Pract, 2020, 38: 101075. doi: 10.1016/j.ctcp.2019.101075
[14] 劳绍贤, 许鑫梅, 周福生, 等. 胃炎消治疗胃癌癌前期病变疗效分析[J]. 中药新药与临床药理, 1997, 8(2): 72-75. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXY702.003.htm
[15] 胡玲, 劳绍贤, 王建华. 胃炎消对胃癌癌前病变bcl-2癌基因mRNA表达的影响[J]. 上海中医药杂志, 2006, 40(1): 27-28. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZZ200601013.htm
[16] 劳绍贤. 胃癌癌前病变基础与临床[M]. 广州: 广东人民出版社, 2002: 96-96.
[17] 马婷婷, 张甘霖, 张博然, 等. 半枝莲和白花蛇舌草药对的研究现状[J]. 中华中医药杂志, 2021, 36(6): 3491-3494. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202106101.htm
[18] 范媛媛, 陈苏宁, 梁靓靓. 姜黄素抗胃癌药理作用机制研究进展[J]. 药物评价研究, 2021, 44(12): 2731-2738. https://www.cnki.com.cn/Article/CJFDTOTAL-YWPJ202112028.htm
[19] 赵益, 孙有智, 肖兵华, 等. 肿节风注射液抗肿瘤实验及对人胃癌SGC-7901细胞周期的影响[J]. 中成药, 2009, 31(7): 997-1000. doi: 10.3969/j.issn.1001-1528.2009.07.006
[20] 赵益, 孙有智, 陈奇. 肿节风注射液体外抗肿瘤作用的实验研究[J]. 中国民族民间医药, 2008, 17(2): 8-9, 36. https://www.cnki.com.cn/Article/CJFDTOTAL-MZMJ200802003.htm
[21] 朱金水, 潘尚铭. 晚期胃癌中西医结合治疗及其细胞免疫功能研究[J]. 中国实验临床免疫学杂志, 1994, 6(5): 43-46.
[22] 吕圭源, 陈素红, 张园, 等. 肿节风挥发油对荷瘤小鼠化疗的增效减毒作用[J]. 浙江中医药大学学报, 2009, 33(1): 116-118. https://www.cnki.com.cn/Article/CJFDTOTAL-BHON200901069.htm
[23] 刘晓曼, 佘世锋, 劳绍贤. 劳绍贤教授治疗脾胃疾病临证用药经验撷萃[J]. 浙江中医药大学学报, 2019, 43(4): 336-338. https://www.cnki.com.cn/Article/CJFDTOTAL-BHON201904011.htm
[24] 李振, 劳绍贤, 郭文峰. 劳绍贤诊治慢性萎缩性胃炎经验[J]. 中国中医基础医学杂志, 2018, 24(5): 691-692. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201805041.htm
[25] 庄昆海, 龚琳, 胡玲. 劳绍贤运用药对治疗脾胃病及杂病经验撷萃[J]. 广州中医药大学学报, 2015, 32(5): 937-939. https://www.cnki.com.cn/Article/CJFDTOTAL-REST201505037.htm
-
计量
- 文章访问数: 979
- PDF下载数: 784
- 施引文献: 0
下载: